이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors

2026년 11월 16일 업데이트: Cogent Biosciences, Inc.

국부적으로 진행되었거나 절제 불가능하거나 전이성인 위장관 기질 종양이 있는 피험자를 대상으로 한 CGT9486+수니티닙 대 수니티닙의 3상 무작위, 공개, 다기관 임상 연구

This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).

연구 개요

연구 유형

중재적

등록 (추정된)

482

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Amsterdam, 네덜란드, 1066 CX
        • 모집하지 않고 적극적으로
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
      • Groningen, 네덜란드, 9713 GZ
        • 모집하지 않고 적극적으로
        • UMC Groningen
      • Nijmegen, 네덜란드, 6525 GA
        • 모집하지 않고 적극적으로
        • Stichting Radboud Universitair Medisch Centrum
      • Rotterdam, 네덜란드, 3015 GD
        • 모집하지 않고 적극적으로
        • Erasmus MC
      • Bergen, 노르웨이, 5021
        • 모집하지 않고 적극적으로
        • Haukeland University Hospital - Bergen
      • Oslo, 노르웨이, 0310
        • 모집하지 않고 적극적으로
        • Oslo University Hospital
      • Kaohsiung City, 대만, 83301
        • 모집하지 않고 적극적으로
        • Chang Gung Memorial Hospital - Kaohsiung Branch
      • New Taipei City, 대만, 10002
        • 모집하지 않고 적극적으로
        • National Taiwan University Hospital
      • Taichung, 대만, 40447
        • 모집하지 않고 적극적으로
        • China Medical University Hospital
      • Taipei, 대만, 11217
        • 모집하지 않고 적극적으로
        • Taipei Veterans General Hospital (VGHTP)
      • Taoyuan, 대만, 33305
        • 모집하지 않고 적극적으로
        • Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
      • Seoul, 대한민국, 03080
        • 모집하지 않고 적극적으로
        • Seoul National University Hospital
      • Seoul, 대한민국, 06351
        • 모집하지 않고 적극적으로
        • Samsung Medical Center
      • Seoul, 대한민국, 08308
        • 모집하지 않고 적극적으로
        • Korea University Guro Hospital
      • Seoul, 대한민국, 05505
        • 모집하지 않고 적극적으로
        • Asan Medical Center
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, 대한민국, 10408
        • 빼는
        • National Cancer Center
      • Aarhus, 덴마크, 8200
        • 모집하지 않고 적극적으로
        • Aarhus University Hospital
      • Bad Saarow, 독일, 15526
        • 모집하지 않고 적극적으로
        • Helios Klinikum Bad Saarow
      • Berlin, 독일, 13125
        • 모집하지 않고 적극적으로
        • Helios Klinikum Berlin-Buch
      • Essen, 독일, 45147
        • 모집하지 않고 적극적으로
        • Universitaetsklinikum Essen
      • Hamburg, 독일, 20246
        • 모집하지 않고 적극적으로
        • Universitaetsklinikum Hamburg-Eppendorf
      • Hanover, 독일, 30625
        • 모집하지 않고 적극적으로
        • Medizinische Hochschule Hannover- Urology Oncology
      • Mannheim, 독일, 68167
        • 모집하지 않고 적극적으로
        • Universitaetsmedizin Mannheim
      • Aguascalientes, 멕시코, 20116
        • 빼는
        • Centro de Investigacion Medica Aquascalientes (CIMA)
      • Monterrey, 멕시코, 64710
        • 모집하지 않고 적극적으로
        • I Can Oncology Center SA De CV
      • Oaxaca City, 멕시코, 68000
        • 빼는
        • Oaxaca Site Management Organization S.C.
    • Alabama
      • Birmingham, Alabama, 미국, 35249
        • 빼는
        • University of Alabama at Birmingham
    • Arizona
      • Scottsdale, Arizona, 미국, 85259
        • 모병
        • Mayo Clinic
      • Tucson, Arizona, 미국, 85719
        • 모집하지 않고 적극적으로
        • University of Arizona- Cancer Center
    • California
      • Duarte, California, 미국, 91010
        • 모병
        • City of Hope
      • Los Angeles, California, 미국, 90404
        • 모집하지 않고 적극적으로
        • University of California, Los Angeles (UCLA)
      • San Diego, California, 미국, 92093
        • 모병
        • University of California, San Diego (UCSD)
      • San Francisco, California, 미국, 94158
        • 모집하지 않고 적극적으로
        • University of California, San Francisco
    • Colorado
      • Denver, Colorado, 미국, 80204
        • 모병
        • University of Colorado Denver
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20010
        • 모병
        • MedStar Washington Hospital Center
    • Florida
      • Jacksonville, Florida, 미국, 32224
        • 모병
        • Mayo Clinic Jacksonville
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami - Sylvester Comprehensive Cancer Center
      • Orange City, Florida, 미국, 32763
        • 빼는
        • Mid Florida Hematology and Oncology Center
      • Orlando, Florida, 미국, 32806
        • 모병
        • Orlando Health Cancer Institute
      • Tampa, Florida, 미국, 33612
        • 모병
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Northwestern University
    • Iowa
      • Iowa City, Iowa, 미국, 52242
        • 모병
        • University of Iowa Hospital and Clinics
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • 모집하지 않고 적극적으로
        • University of Kansas Cancer Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • 모병
        • Dana-Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • University of Michigan Comprehensive Cancer Center
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic
    • Missouri
      • St Louis, Missouri, 미국, 63130
        • 모병
        • Washington University
    • Nebraska
      • Omaha, Nebraska, 미국, 68114
        • 모병
        • Nebraska Methodist Hospital
    • New York
      • Buffalo, New York, 미국, 14203
        • 모집하지 않고 적극적으로
        • Roswell Park Comprehensive Cancer Center
      • New York, New York, 미국, 10021
        • 모병
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Durham, North Carolina, 미국, 27705
        • 모병
        • Duke University
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • The Cleveland Clinic Foundation
      • Columbus, Ohio, 미국, 43210
        • 모병
        • The Ohio State University Comprehensive Cancer Center
      • Toledo, Ohio, 미국, 43614
        • 빼는
        • University of Toledo Medical Center
    • Oregon
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health & Science University (OHSU)
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19111
        • 모병
        • Fox Chase Cancer Center
      • Pittsburgh, Pennsylvania, 미국, 15232
        • 모병
        • University of Pittsburgh Medical Center - Hillman Cancer Center
    • Tennessee
      • Knoxville, Tennessee, 미국, 37920
        • 빼는
        • University of Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University Medical Center
    • Texas
      • Houston, Texas, 미국, 77030-4009
        • 모병
        • The University of Texas MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, 미국, 98109
        • 모집하지 않고 적극적으로
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Madison, Wisconsin, 미국, 53705
        • 모병
        • University of Wisconsin - Carbone Cancer Center
      • Campinas, 브라질, 130.83-888
        • 모집하지 않고 적극적으로
        • Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
      • Rio de Janeiro, 브라질, 20.230-130
        • 모집하지 않고 적극적으로
        • lnstituto Nacional de Cancer - INCA
      • São Paulo, 브라질, 09060-650
        • 모집하지 않고 적극적으로
        • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
      • Lund, 스웨덴, 22185
        • 모집하지 않고 적극적으로
        • Skane University Hospital Lund
      • Solna, 스웨덴, 171 76
        • 모집하지 않고 적극적으로
        • Karolinska University Hospital
      • Barcelona, 스페인, 08035
        • 모집하지 않고 적극적으로
        • Hospital Universitario Vall d'Hebron
      • Barcelona, 스페인, 08041
        • 빼는
        • Hospital de la Santa Creu i Sant Pau Barcelona
      • Barcelona, 스페인, 08908
        • 모집하지 않고 적극적으로
        • Institut Catala d'Oncologia - L'Hospitalet
      • El Palmar, 스페인, 30120
        • 빼는
        • Hospital Clinico Universitario Virgen de la Arrixaca
      • Madrid, 스페인, 28041
        • 모집하지 않고 적극적으로
        • Hospital Universitario 12 de Octubre
      • Madrid, 스페인, 28040
        • 모집하지 않고 적극적으로
        • Hospital Clinico San Carlos
      • Madrid, 스페인, 28007
        • 모집하지 않고 적극적으로
        • Hospital General Universitario Gregorio Maranon
      • Madrid, 스페인, 28040
        • 모집하지 않고 적극적으로
        • Hospital Fundación Jiménez Díaz
      • Santiago de Compostela, 스페인, 15706
        • 모집하지 않고 적극적으로
        • Hospital Clinico Universitario de Santiago de Compostela
      • Seville, 스페인, 41013
        • 모집하지 않고 적극적으로
        • Hospital Universitario Virgen del Rocio
      • Zaragoza, 스페인, 50009
        • 빼는
        • Hospital Universitario Miguel Servet
      • Buenos Aires, 아르헨티나, C1426ANZ
        • 모집하지 않고 적극적으로
        • Instituto Alexander Fleming
      • Córdoba, 아르헨티나, X5000HWE
        • 모집하지 않고 적극적으로
        • Instituto Oncologico de Cordoba (IONC)
      • Cambridge, 영국, CB2 0QQ
        • 모집하지 않고 적극적으로
        • Cambridge Addenbrooke's Hospital
      • Glasgow, 영국, G12 0YN
        • 빼는
        • Beatson, West of Scotland Cancer Centre
      • London, 영국, NW1 2PG
        • 모집하지 않고 적극적으로
        • University College London Hospital
      • London, 영국, SW3 6JJ
        • 모집하지 않고 적극적으로
        • Royal Marsden Hospital - Surrey
      • London, 영국, SE1 9RT
        • 빼는
        • Guy's Hospital
      • Manchester, 영국, M20 4BX
        • 모집하지 않고 적극적으로
        • The Christie NHS Foundation Trust
      • Sheffield, 영국, S10 2SJ
        • 모집하지 않고 적극적으로
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Aviano, 이탈리아, 33081
        • 모집하지 않고 적극적으로
        • Centro Riferimento Oncologico - Aviano
      • Bologna, 이탈리아, 40138
        • 모집하지 않고 적극적으로
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
      • Brescia, 이탈리아, 25123
        • 모집하지 않고 적극적으로
        • ASST degli Spedali Civili di Brescia
      • Candiolo, 이탈리아, 10060
        • 빼는
        • IRCCS La Fondazione e l'Istituto di Candiolo
      • Florence, 이탈리아, 50134
        • 모집하지 않고 적극적으로
        • Azienda Ospedaliero-Universitaria Careggi
      • Meldola, 이탈리아, 47014
        • 모집하지 않고 적극적으로
        • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
      • Milan, 이탈리아, 20133
        • 모집하지 않고 적극적으로
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, 이탈리아, 20141
        • 모집하지 않고 적극적으로
        • Istituto Europeo di Oncologia
      • Palermo, 이탈리아, 90127
        • 모집하지 않고 적극적으로
        • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
      • Roma, 이탈리아, 00128
        • 모집하지 않고 적극적으로
        • Policlinico Universitario Campus Bio-Medico
      • Rozzano, 이탈리아, 20089
        • 모집하지 않고 적극적으로
        • Istituto Clinico Humanitas
      • Verona, 이탈리아, 31726
        • 모집하지 않고 적극적으로
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Brno, 체코, 65653
        • 모집하지 않고 적극적으로
        • Masarykuv onkologicky ustav
      • Hradec Králové, 체코, 500 05
        • 빼는
        • Fakultni nemocnice Hradec Kralove
      • Olomouc, 체코, 77900
        • 모집하지 않고 적극적으로
        • Fakultni nemocnice Olomouc - Oncology clinic
      • Santiago, 칠레, 7500921
        • 모집하지 않고 적극적으로
        • Instituto Oncologico FALP
      • Santiago, 칠레, 7560908
        • 모집하지 않고 적극적으로
        • Centro de Oncologia de Precision, Universidad Mayor
      • Calgary, 캐나다, T2N 4N2
        • 모병
        • Tom Baker Cancer Center
      • Montreal, 캐나다, HIT 2M4
        • 모집하지 않고 적극적으로
        • Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
    • Alberta
      • Edmonton, Alberta, 캐나다, T6G 1Z2
        • 모병
        • Alberta Health Services Cross Cancer Institute
    • Ontario
      • Toronto, Ontario, 캐나다, M5G 2M9
        • 모병
        • Princess Margaret Hospital
      • Brzozów, 폴란드, 36-200
        • 모집하지 않고 적극적으로
        • Szpital Specjalistyczny w Brzozowie
      • Bydgoszcz, 폴란드, 85-796
        • 빼는
        • Centrum Onkologii im. Prof. Franciszka Lukaszczyka
      • Gliwice, 폴란드, 44-102
        • 모집하지 않고 적극적으로
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
      • Warsaw, 폴란드, 02-781
        • 모집하지 않고 적극적으로
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
      • Bordeaux, 프랑스, 33076
        • 모집하지 않고 적극적으로
        • Institut Bergonie
      • Lille, 프랑스, 59000
        • 모집하지 않고 적극적으로
        • Centre Oscar Lambret
      • Lyon, 프랑스, 69008
        • 모집하지 않고 적극적으로
        • Centre Leon Berard
      • Marseille, 프랑스, 13005
        • 모집하지 않고 적극적으로
        • AP-HM - Hôpital de la Timone
      • Rennes, 프랑스, 35042
        • 모집하지 않고 적극적으로
        • Centre Eugene Marquis
      • Saint-Herblain, 프랑스, 44800
        • 모집하지 않고 적극적으로
        • ICO St-Herblain
      • Toulouse, 프랑스, 31400
        • 모집하지 않고 적극적으로
        • CHU de Toulouse - Hospital Rangueil
      • Villejuif, 프랑스, 94805
        • 모집하지 않고 적극적으로
        • Gustave Roussy
      • Debrecen, 헝가리, 4032
        • 모집하지 않고 적극적으로
        • Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
      • Bankstown, 호주, 2200
        • 모집하지 않고 적극적으로
        • Bankstown-Lidcombe Hospital
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • 모집하지 않고 적극적으로
        • Sir Charles Gairdner Hospital
      • Central, 홍콩
        • 빼는
        • Humanity & Health Clinical Trial Centre
      • Jordon, 홍콩
        • 모집하지 않고 적극적으로
        • Hong Kong United Oncology Centre
      • Shatin, 홍콩
        • 모집하지 않고 적극적으로
        • Prince of Wales Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  1. Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)

  2. Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)

  3. Participants must have received the following treatment:

    • DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
    • Part 1b: Treatment with ≥2 prior TKI for GISTs
    • Part 2: Prior treatment with imatinib only
    • GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
  4. Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)

  5. Eastern Cooperative Oncology Group (ECOG) Status

    • 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
    • 0 to 1 (GIST 1L Substudy)
  6. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits

Key Exclusion Criteria:

  1. Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
  2. Clinically significant cardiac disease
  3. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
  4. Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
  5. Any active bleeding excluding hemorrhoidal or gum bleeding
  6. Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
  7. Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
  8. Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
  9. Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 1a

Bezuclastinib plus sunitinib 37.5 mg once a day (QD)

Participants will receive bezuclastinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

실험적: Part 2 - Experimental Group

Bezuclastinib plus sunitinib 37.5 mg QD

Participants will receive bezuclastinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

활성 비교기: Part 2 - Control Group

Sunitinib 37.5 mg QD

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

실험적: Part 1b - DDI Cohort 1

Bezuclastinib plus sunitinib 37.5 mg QD

Participants will receive bezuclastinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

실험적: Part 1b - DDI Cohort 2

Sunitinib 37.5 mg QD plus bezuclastinib

Participants will receive bezuclastinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

실험적: DDI Substudy (Midazolam)

Midazolam, bezuclastinib, sunitinib

Participants will receive bezuclastinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

Participants will receive a single-dose of midazolam on Day 1 and Day 15

실험적: GIST 1L Substudy

Bezuclastinib, sunitinib

Participants will receive bezuclastinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib orally until study stopping rules are met.

Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met.

Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.

다른 이름들:
  • CGT9486

Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1a - pharmacokinetics - Cmax
기간: 16 days

Maximum plasma concentration (Cmax)

16 days
Part 1a - pharmacokinetics - AUC
기간: 16 days

Area under the plasma concentration-time curve (AUC)

16 days
Part 1b - pharmacokinetics - Cmax
기간: 14 days

Maximum plasma concentration (Cmax)

14 days
Part 1b - pharmacokinetics - AUC
기간: 14 days

Area under the plasma concentration-time curve (AUC)

14 days
Part 1b - pharmacokinetics - Tmax
기간: 14 days

Time to maximum observed plasma concentration (Tmax)

14 days
Part 2 - Progression Free Survival (PFS)
기간: Approximately 48 months

Time from first dose to documented disease progression or death due to any cause, whichever occurs first

Approximately 48 months
DDI Substudy - pharmacokinetics - AUC
기간: 16 days

Area under the plasma concentration-time curve (AUC)

16 days
DDI Substudy - pharmacokinetics - Cmax
기간: 14 days

Maximum plasma concentration (Cmax)

14 days

2차 결과 측정

결과 측정
측정값 설명
기간
All Study Parts - observing the safety of each treatment regimen.
기간: Approximately 48 months

Incidence and severity of Adverse Events from first dose of study drug

Approximately 48 months
All Study Parts - observing the safety of each treatment regimen.
기간: Approximately 48 months

Incidence and severity of Serious Adverse Events from first dose of study drug

Approximately 48 months
All Study Parts - observing the safety of each treatment regimen.
기간: Approximately 48 months

Incidence of Adverse Events leading to dose modifications from first dose of study drug

Approximately 48 months
All Study Parts - observing the safety of each treatment regimen.
기간: Approximately 48 months

Change from baseline in laboratory results

Approximately 48 months
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
기간: Approximately 48 months

Time from first dose to death due to any cause

Approximately 48 months
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
기간: Approximately 48 months

Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Approximately 48 months
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
기간: Approximately 48 months

Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks

Approximately 48 months
Part 1a, Part 1b. Part 2 - Time to response (TTR)
기간: Approximately 48 months

Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1

Approximately 48 months
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
기간: Approximately 48 months

Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first

Approximately 48 months
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
기간: Approximately 48 months

Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms.

Approximately 48 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 4월 14일

기본 완료 (실제)

2025년 9월 30일

연구 완료 (추정된)

2030년 1월 1일

연구 등록 날짜

최초 제출

2021년 12월 23일

QC 기준을 충족하는 최초 제출

2022년 1월 14일

처음 게시됨 (실제)

2022년 1월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다